CA2251071A1 - Use of an osmolyte in the preparation of a medicament for treating complications resulting from ischemia - Google Patents

Use of an osmolyte in the preparation of a medicament for treating complications resulting from ischemia Download PDF

Info

Publication number
CA2251071A1
CA2251071A1 CA002251071A CA2251071A CA2251071A1 CA 2251071 A1 CA2251071 A1 CA 2251071A1 CA 002251071 A CA002251071 A CA 002251071A CA 2251071 A CA2251071 A CA 2251071A CA 2251071 A1 CA2251071 A1 CA 2251071A1
Authority
CA
Canada
Prior art keywords
osmolyte
cells
use according
betaine
complications
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002251071A
Other languages
English (en)
French (fr)
Inventor
Dieter Haussinger
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
USSINGER DIETER H
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2251071A1 publication Critical patent/CA2251071A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA002251071A 1996-04-12 1997-04-14 Use of an osmolyte in the preparation of a medicament for treating complications resulting from ischemia Abandoned CA2251071A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9601396A SE9601396D0 (sv) 1996-04-12 1996-04-12 New therapeutic treatment 2
SE9601396-6 1996-04-12

Publications (1)

Publication Number Publication Date
CA2251071A1 true CA2251071A1 (en) 1997-10-23

Family

ID=20402175

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002251071A Abandoned CA2251071A1 (en) 1996-04-12 1997-04-14 Use of an osmolyte in the preparation of a medicament for treating complications resulting from ischemia

Country Status (7)

Country Link
EP (1) EP0946167A1 (no)
JP (1) JP2000508651A (no)
AU (1) AU2386097A (no)
CA (1) CA2251071A1 (no)
NO (1) NO984759D0 (no)
SE (1) SE9601396D0 (no)
WO (1) WO1997038685A1 (no)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6080788A (en) * 1997-03-27 2000-06-27 Sole; Michael J. Composition for improvement of cellular nutrition and mitochondrial energetics
US7608640B2 (en) 1999-03-02 2009-10-27 Jallal Messadek Glycine betaine and its use
BE1012495A3 (fr) 1999-03-02 2000-11-07 Messadek Jallal La glycine-betaine pour son usage antithrombotique.
AU5812800A (en) 1999-06-12 2001-01-02 Stefan Barth Pharmaceutical preparation
ATE283054T1 (de) * 2000-04-12 2004-12-15 Bitop Ag Verwendung von kompatiblen soluten als substanzen mit radikalfangenden eigenschaften
JP5084089B2 (ja) * 2001-06-14 2012-11-28 大塚製薬株式会社 医薬組成物
BE1015608A6 (fr) 2003-07-15 2005-06-07 Messadek Jallal Traitement des arterites.
DE10330768A1 (de) * 2003-07-07 2005-02-24 bitop Aktiengesellschaft für biotechnische Optimierung Verwendung von aus extremophilen Bakterien gewonnenen Osmolyten zur Herstellung von inhalierbaren Arzneimitteln zur Prophylaxe und Behandlung pulmonaler und kardiovaskulärer Erkrankungen, sowie eines Osmolyte als Wirkstoffbestandteil enthaltende Inhalationsvorrichtung
WO2006050581A2 (en) * 2004-11-10 2006-05-18 Jallal Messadek Betaine as agent against arthropod - or mosquito -borne diseases
EP2242489A1 (en) 2005-02-15 2010-10-27 Jallal Messadek Combination therapeutic compositions and method of use
EP1885392B1 (en) 2005-04-27 2012-01-11 Jallal Messadek Insulins combinations
DE102008006780A1 (de) * 2008-01-30 2009-08-06 Bitop Ag Verwendung von Tetrahydropyrimidinen

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE464059C (sv) * 1988-09-15 1997-06-02 Perstorp Ab Användning av inositoltrifosfat för framställning av läkemedel
JP2642198B2 (ja) * 1989-08-24 1997-08-20 元庸 村上 胃粘膜障害治療剤
SE8904355D0 (sv) * 1989-12-21 1989-12-21 Perstorp Ab Medicament
WO1991014435A1 (en) * 1990-03-19 1991-10-03 Brigham And Women's Hospital Treatment of osmotic disturbance with organic osmolytes
US5312839A (en) * 1991-03-05 1994-05-17 Regents Of The University Of California Compounds and method for protection of cells and tissues from irreversible injury due to lactic acidosis
BE1007500A3 (fr) * 1992-09-18 1995-07-18 Pasteur Merieux Serums Vacc Solution de perfusion, de conservation et de reperfusion d'organes.
US5582839A (en) * 1995-04-18 1996-12-10 Nutrition 21 Magnesium taurate and other mineral taurates

Also Published As

Publication number Publication date
JP2000508651A (ja) 2000-07-11
WO1997038685A1 (en) 1997-10-23
EP0946167A1 (en) 1999-10-06
NO984759L (no) 1998-10-12
AU2386097A (en) 1997-11-07
SE9601396D0 (sv) 1996-04-12
NO984759D0 (no) 1998-10-12

Similar Documents

Publication Publication Date Title
US5880098A (en) Therapeutic treatment
Bugger et al. Mitochondrial ROS in myocardial ischemia reperfusion and remodeling
Cannistrà et al. Hepatic ischemia reperfusion injury: A systematic review of literature and the role of current drugs and biomarkers
EP0464084B1 (en) Use of eicosapentaenoic acid for the treatment of cachexia
Higuchi et al. Ethanol‐induced apoptosis and oxidative stress in hepatocytes
Hoffman et al. Myocardial reperfusion injury: etiology, mechanisms, and therapies
Beal Bioenergetic approaches for neuroprotection in Parkinson's disease
Bolcal et al. Protective effects of antioxidant medications on limb ischemia reperfusion injury
Mickle et al. Myocardial salvage with trolox and ascorbic acid for an acute evolving infarction
Ly et al. Transplasma membrane electron transport: enzymes involved and biological function
Buehler et al. Effects of endogenous ascorbate on oxidation, oxygenation, and toxicokinetics of cell-free modified hemoglobin after exchange transfusion in rat and guinea pig
CA2251071A1 (en) Use of an osmolyte in the preparation of a medicament for treating complications resulting from ischemia
US20030124503A1 (en) Pyruvate cardioplegia solutions for administration to the heart during cardiopulmonary surgery and methods of use thereof
US20120041006A1 (en) Compositions for Raising Uric Acid Levels and Methods of Using the Same
US5843996A (en) Intravenous magnesium gluconate for treatment of conditions caused by excessive oxidative stress due to free radical distribution
Fudaba et al. Geranylgeranylacetone, a heat shock protein inducer, prevents primary graft nonfunction in rat liver transplantation
McCord et al. Mitochondrial injury by ischemia and reperfusion
Bezinover et al. Use of a third-generation perfluorocarbon for preservation of rat DCD liver grafts
EP0910361A1 (en) Use of an osmolyte for treating the effects of an infection, an inflammation or an immune dysfunction
Mikrut et al. The effect of bradykinin on the oxidative state of rats with acute hyperglycaemia
Kajiwara et al. The influence of oxygen free radical scavengers on the reduction of membrane-bound Na+-K+-ATPase activity induced by ischemia/reperfusion injury in the canine kidney
Gassen et al. Apomorphine is a potent radical scavenger and protects cultured pheochromocytoma cells from 6-OHDA and H2O2-induced cell death
CN115414344B (zh) L-瓜氨酸在制备防治铁过载药物中的应用
KR20200118851A (ko) 신규 아미노티올로 허혈-재관류에 의해 유발된 세포사멸을 감소하는 방법
US20230056314A1 (en) Cytoprotective compositions for short-term cells storage and transportation without cryopreservation and deep freezing

Legal Events

Date Code Title Description
FZDE Dead